| Atharva Thakore, MD | |
|
1024 S Lemay Ave, Fort Collins, CO 80524-3929 | |
| (970) 495-7000 | |
| Not Available |
| Full Name | Atharva Thakore |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 7 Years |
| Location | 1024 S Lemay Ave, Fort Collins, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154853125 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical Center Of The Rockies | Loveland, CO | Hospital |
| Uchealth Greeley Hospital | Greeley, CO | Hospital |
| Poudre Valley Hospital | Fort collins, CO | Hospital |
| Sidney Regional Medical Center | Sidney, NE | Hospital |
| Uchealth Yampa Valley Medical Center | Steamboat springs, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fort Collins Radiologic Associates Pc | 7315844396 | 55 |
| Poudre Valley Medical Group Llc | 9638208549 | 1605 |
| Uchealth Imaging Services Llc | 5799021291 | 141 |
| Yampa Valley Medical Center | 5890685689 | 122 |
News Archive
Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.
WellPoint, Inc. (NYSE: WLP) today announced that third quarter 2009 net income was $730.2 million, or $1.53 per share, including net investment gains of $21.5 million pre-tax, or $0.03 per share, and an impairment charge totaling $205.5 million pre-tax, or $0.28 per share, for certain intangible assets.
For the first time since the corresponding law became effective in 2012, the German Institute for Quality and Efficiency in Health Care has published an assessment of the potential of a new treatment method according to §137e of Social Code Book V.
A new study published in the Journal of the American Osteopathic Association suggested that the concussion symptoms suffered by adolescent female athletes last twice as long as their male counterparts.
Contrary to previous media reports, a new study led by Vanderbilt University Medical Center researchers finds that Medicare Part D prescription drug insurance plans largely favor generic drugs over brand-name counterparts.
› Verified 5 days ago
| Entity Name | Fort Collins Radiologic Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003849498 PECOS PAC ID: 7315844396 Enrollment ID: O20031217000768 |
News Archive
Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.
WellPoint, Inc. (NYSE: WLP) today announced that third quarter 2009 net income was $730.2 million, or $1.53 per share, including net investment gains of $21.5 million pre-tax, or $0.03 per share, and an impairment charge totaling $205.5 million pre-tax, or $0.28 per share, for certain intangible assets.
For the first time since the corresponding law became effective in 2012, the German Institute for Quality and Efficiency in Health Care has published an assessment of the potential of a new treatment method according to §137e of Social Code Book V.
A new study published in the Journal of the American Osteopathic Association suggested that the concussion symptoms suffered by adolescent female athletes last twice as long as their male counterparts.
Contrary to previous media reports, a new study led by Vanderbilt University Medical Center researchers finds that Medicare Part D prescription drug insurance plans largely favor generic drugs over brand-name counterparts.
› Verified 5 days ago
| Entity Name | Yampa Valley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790787307 PECOS PAC ID: 5890685689 Enrollment ID: O20040316001301 |
News Archive
Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.
WellPoint, Inc. (NYSE: WLP) today announced that third quarter 2009 net income was $730.2 million, or $1.53 per share, including net investment gains of $21.5 million pre-tax, or $0.03 per share, and an impairment charge totaling $205.5 million pre-tax, or $0.28 per share, for certain intangible assets.
For the first time since the corresponding law became effective in 2012, the German Institute for Quality and Efficiency in Health Care has published an assessment of the potential of a new treatment method according to §137e of Social Code Book V.
A new study published in the Journal of the American Osteopathic Association suggested that the concussion symptoms suffered by adolescent female athletes last twice as long as their male counterparts.
Contrary to previous media reports, a new study led by Vanderbilt University Medical Center researchers finds that Medicare Part D prescription drug insurance plans largely favor generic drugs over brand-name counterparts.
› Verified 5 days ago
| Entity Name | Poudre Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366763260 PECOS PAC ID: 9638208549 Enrollment ID: O20100602000122 |
News Archive
Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.
WellPoint, Inc. (NYSE: WLP) today announced that third quarter 2009 net income was $730.2 million, or $1.53 per share, including net investment gains of $21.5 million pre-tax, or $0.03 per share, and an impairment charge totaling $205.5 million pre-tax, or $0.28 per share, for certain intangible assets.
For the first time since the corresponding law became effective in 2012, the German Institute for Quality and Efficiency in Health Care has published an assessment of the potential of a new treatment method according to §137e of Social Code Book V.
A new study published in the Journal of the American Osteopathic Association suggested that the concussion symptoms suffered by adolescent female athletes last twice as long as their male counterparts.
Contrary to previous media reports, a new study led by Vanderbilt University Medical Center researchers finds that Medicare Part D prescription drug insurance plans largely favor generic drugs over brand-name counterparts.
› Verified 5 days ago
| Entity Name | Uchealth Imaging Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396210902 PECOS PAC ID: 5799021291 Enrollment ID: O20190103002022 |
News Archive
Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.
WellPoint, Inc. (NYSE: WLP) today announced that third quarter 2009 net income was $730.2 million, or $1.53 per share, including net investment gains of $21.5 million pre-tax, or $0.03 per share, and an impairment charge totaling $205.5 million pre-tax, or $0.28 per share, for certain intangible assets.
For the first time since the corresponding law became effective in 2012, the German Institute for Quality and Efficiency in Health Care has published an assessment of the potential of a new treatment method according to §137e of Social Code Book V.
A new study published in the Journal of the American Osteopathic Association suggested that the concussion symptoms suffered by adolescent female athletes last twice as long as their male counterparts.
Contrary to previous media reports, a new study led by Vanderbilt University Medical Center researchers finds that Medicare Part D prescription drug insurance plans largely favor generic drugs over brand-name counterparts.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Atharva Thakore, MD 2008 Caribou Dr, Fort Collins, CO 80525-4325 Ph: (970) 484-4757 | Atharva Thakore, MD 1024 S Lemay Ave, Fort Collins, CO 80524-3929 Ph: (970) 495-7000 |
News Archive
Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.
WellPoint, Inc. (NYSE: WLP) today announced that third quarter 2009 net income was $730.2 million, or $1.53 per share, including net investment gains of $21.5 million pre-tax, or $0.03 per share, and an impairment charge totaling $205.5 million pre-tax, or $0.28 per share, for certain intangible assets.
For the first time since the corresponding law became effective in 2012, the German Institute for Quality and Efficiency in Health Care has published an assessment of the potential of a new treatment method according to §137e of Social Code Book V.
A new study published in the Journal of the American Osteopathic Association suggested that the concussion symptoms suffered by adolescent female athletes last twice as long as their male counterparts.
Contrary to previous media reports, a new study led by Vanderbilt University Medical Center researchers finds that Medicare Part D prescription drug insurance plans largely favor generic drugs over brand-name counterparts.
› Verified 5 days ago
Dr. Tracy Haefele Florant, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 430 Spinnaker Ln, Fort Collins, CO 80525 Phone: 970-988-8637 | |
Karl E. Magsamen, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 Fax: 970-495-7639 | |
Dr. Karen B Alderfer, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 | |
Dr. Nathan Miller, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 | |
Dr. Kevin Limbaugh, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-8600 Fax: 970-495-7619 | |
Dr. Guy Thomas Alexander, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 | |
Dr. Aaron Michael Frenette, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1024 S Lemay Ave, Fort Collins, CO 80524 Phone: 970-495-7000 |